688315
vs
S
Shanghai Composite
688315
Over the past 12 months, Novogene Co Ltd has underperformed Shanghai Composite, delivering a return of +3% compared to the Shanghai Composite's +28% growth.
Stocks Performance
688315 vs Shanghai Composite
Performance Gap
688315 vs Shanghai Composite
Performance By Year
688315 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Novogene Co Ltd
Glance View
Novogene Co., Ltd. engages in the provision of genomic services and solutions. The company is headquartered in Beijing, Beijing and currently employs 2,284 full-time employees. The company went IPO on 2021-04-13. The firm mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. At the same time, based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The firm's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The firm conducts its businesses in domestic and overseas markets.
